Increased Twist expression in advanced stage of mycosis fungoides and Sezary syndrome

被引:26
|
作者
Goswami, Meghali [1 ]
Duvic, Madeleine [1 ]
Dougherty, Alexis [1 ]
Ni, Xiao [1 ]
机构
[1] Univ Texas MD Anderson Canc Ctr, Dept Dermatol, Houston, TX 77030 USA
关键词
c-myc; mycosis fungoides; p53; Sezary syndrome; Twist; T-CELL LYMPHOMA; EPITHELIAL-MESENCHYMAL TRANSITION; GENE-EXPRESSION; UP-REGULATION; INTERNATIONAL-SOCIETY; CUTANEOUS-LYMPHOMAS; PROGNOSTIC-FACTORS; DOWN-REGULATION; CANCER; STAT3;
D O I
10.1111/j.1600-0560.2012.01883.x
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Background: The mechanisms of tumor progression in mycosis fungoides (MF) and Sezary syndrome (SS) are poorly understood. Twist, a transcription factor, is thought to promote solid tumor progression by blocking p53 and inhibiting c-myc-induced apoptosis. Whether Twist expression is correlated to MF/SS stages remains unknown. Methods: Twist, c-myc and p53 proteins in 68 MF/SS lesions across all T stages were examined by immunohistochemistry, and mRNA levels in peripheral blood CD4+ T-cells from SS patients were measured by real-time quantitative polymerase chain reaction. Results: Positive staining for Twist was found in 12.5% (2/16) of T1 and 33.3% (7/21) of T2 early stage patches/plaques compared to 50.0% (9/18) of T3 tumors and 84.6% (11/13) of T4 erythroderma. Most T4 erythroderma were positive for Twist in dermal lymphocytes, with the strongest staining. Positive staining for c-myc was higher in T3/T4 lesions (29/31, 93.5%) than T1/T2 lesions (25/37, 67.6%, p < 0.05), with strongest staining in T3 tumors. Aberrant p53 expression was more common in T3/T4 lesions (8/31, 25.8%) than in T1/T2 lesions (2/37, 5.4%, p < 0.05). Twist mRNA was detected in all CD4+ T cells from SS patients but not in normal donors. Conclusions: Increased Twist protein expression in advanced MF/SS lesions suggests that Twist expression may correlate with MF/SS stages.
引用
收藏
页码:500 / 507
页数:8
相关论文
共 50 条
  • [1] Systemic Treatment Options for Advanced-Stage Mycosis Fungoides and Sezary Syndrome
    Photiou, Louise
    van der Weyden, Carrie
    McCormack, Christopher
    Prince, H. Miles
    CURRENT ONCOLOGY REPORTS, 2018, 20 (04)
  • [2] Mycosis Fungoides and Sezary Syndrome
    Foss, Francine M.
    Girardi, Michael
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2017, 31 (02) : 297 - +
  • [3] TOX Expression in Mycosis Fungoides and Sezary Syndrome
    Pileri, Alessandro
    Cavicchi, Martina
    Bertuzzi, Clara
    Righi, Simona
    Zengarini, Corrado
    Sabattini, Elena
    Roncador, Giovanna
    Agostinelli, Claudio
    DIAGNOSTICS, 2022, 12 (07)
  • [4] Mycosis Fungoides and Sezary Syndrome: An Update
    Larocca, Cecilia
    Kupper, Thomas
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2019, 33 (01) : 103 - +
  • [5] Mycosis fungoides and Sezary syndrome
    Lee, Hyewon
    BLOOD RESEARCH, 2023, 58 : 66 - 82
  • [6] Romidepsin and total skin electron beam therapy in advanced stage mycosis fungoides and Sezary syndrome
    Jothishankar, Balaji
    Almazan, Tim
    Kim, Youn
    Liauw, Stanley
    Smith, Sonali
    Kline, Justin
    Abdulla, Farah
    BRITISH JOURNAL OF HAEMATOLOGY, 2019, 186 (02) : 377 - 379
  • [7] Sezary syndrome and mycosis fungoides: An overview, including the role of immunophenotyping
    Pulitzer, Melissa P.
    Horna, Pedro
    Almeida, Julia
    CYTOMETRY PART B-CLINICAL CYTOMETRY, 2021, 100 (02) : 132 - 138
  • [8] Mycosis fungoides and Sezary syndrome
    Jonak, Constanze
    Tittes, Julia
    Brunner, Patrick Manfred
    Guenova, Emmanuella
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2021, 19 (09): : 1307 - 1332
  • [9] On the Way to Curing Advanced-Stage Mycosis Fungoides/Sézary Syndrome
    Purnak, Seda
    Hosing, Chitra
    Dabaja, Bouthaina
    Bassett, Roland L.
    Huen, Auris
    Duvic, Madeleine
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 (12) : 827 - 836
  • [10] Multidisciplinary Management of Mycosis Fungoides/Sezary Syndrome
    Berg, Sara
    Villasenor-Park, Jennifer
    Haun, Paul
    Kim, Ellen J.
    CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 2017, 12 (03) : 234 - 243